The share price of
) reached a new 52-week high, touching $24.07 on Jul 8, 2013. The
closing price (as of Jul 8) of this San Diego, Calif - based
specialty biopharmaceutical company reflects a massive
year-to-date return of 108.1%. The average volume of shares
traded over the last three months stood at approximately 989K.
The company had a market capitalization of $1.53 billion on Jul
Furthermore, Santarus has delivered a massive average positive
earnings surprise of 200.2% over the last four quarters. The
long-term expected earnings growth rate for this stock is
Earlier this year, Santarus received a major boost when the US
Food and Drug Administration (FDA) approved Uceris for the
induction of remission in patients suffering from
mild-to-moderate ulcerative colitis. The product was launched in
the US in Feb 2013, earlier than the company's initial launch
date of Mar 2013. Santarus' shares were up significantly on the
FDA approval of Uceris. We are positive on the Uceris launch -
Uceris is off to a strong start and should continue performing
well. Santarus reported Uceris sales of $6.6 million in the first
quarter of 2013.
We are also positive on the company's efforts to stem the
decline in prescription trends for the branded Zegerid. Santarus
resumed promotion of Zegerid in Feb 2013.
We note that Santarus has an impressive pipeline with phase
III candidates such as Ruconest and rifamycin SV MMX.
Ruconest is currently under FDA review for the treatment of
hereditary angioedema (HAE) patients suffering from acute
angioedema attacks. Ruconest is already approved in Europe for
the same indication. We note that it enjoys orphan drug status in
the US for treating acute attacks of HAE as well as for the
prophylactic treatment of HAE. Once approved, Ruconest could have
12 years of data exclusivity.
We expect investor focus to remain on the Uceris launch, the
Zegerid re-launch and the outcome of the FDA advisory panel
meeting for Ruconest.
Over the last 60 days, the Zacks Consensus Estimate for 2013
has marginally gone up from $0.84 to $0.85 per share. Meanwhile,
the Zacks Consensus Estimate for 2014 has risen from $1.21 to
$1.32 per share.
Other Stocks to Consider
Santarus currently carries a Zacks Rank #1 (Strong Buy). At
present, companies like
Cadence Pharmaceuticals Inc.
) also carry a comparable rank.
CADENCE PHARMA (CADX): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.